The above data suggest that the upregulation of costimulatory receptors such as ICOS on the surface of malignant T cells may be involved in the development of SS, and the ICOS-ICOS ligand costimulatory pathway may be a promising target in cutaneous T-cell lymphoma immunotherapy [37]. Here, ICOS is linked to primary cutaneous T-cell non-Hodgkin lymphoma.